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Novel Method of Percutaneous Mitral Valve
epair for Ischemic Mitral Regurgitation
aul Sorajja, MD, FACC,* Rick A. Nishimura, MD, FACC,* Jess Thompson, MD,*
enton Zehr, MD†
ochester, Minnesota; and Pittsburgh, Pennsylvania
bjectives This investigation sought to determine the feasibility of a novel method of a percutane-
us mitral valve repair.
ackground Percutaneous mitral valve repair has emerged as an alternative therapy for patients
ith functional mitral regurgitation. However, current methods that rely on cannulation of the coro-
ary sinus may not result in direct reduction of the mitral annulus area due to the superior relation-
hip of the sinus to the annulus.
ethods A novel device, consisting of helical stainless steel screws connected by a biocompatible
ether, was designed for percutaneous mitral valve repair. This device was implanted by implanting
he helical screws directly into the myocardium at the posteromedial mitral annulus of 8 anesthe-
ized pigs from the right internal jugular vein.
esults Implantation of the device resulted in a 19.7  0.1% reduction in mitral annular area and
n 18.8  0.1% decrease in the mitral anterior-posterior dimension (both p  0.05 vs. baseline). This
nnular reduction persisted at 3-month follow-up. Both the coronary sinus and left circumﬂex coro-
ary artery remained patent in all animals. There was no evidence of device migration, poor wound
ealing, or tissue thrombosis at the sites of device implantation.
onclusions Percutaneous mitral valve repair targeting the ventricular myocardium from central
enous access is feasible. By directly acting on the posteromedial mitral annulus, this methodology
argets the mitral annular area most frequently affected by ischemic mitral regurgitation, lessens the
isk of coronary artery impingement, promotes coronary sinus patency, and overcomes technical
oncerns that may arise when the coronary sinus lies signiﬁcantly superior to the mitral
nnulus. (J Am Coll Cardiol Intv 2008;1:663–72) © 2008 by the American College of Cardiology
oundation
rom the *Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota;
nd the †Department of Cardiac Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. Funding for this
tudy was provided entirely by St. Jude Medical Inc. Cardiac Technologies Group. The sponsor had full access to the data and
reparation of the manuscript. Dr. Sorajja has served as a consultant to St. Jude Medical Inc. Cardiac Technologies Group. Dr.
ehr is a patent holder and has a royalty agreement with the technology described in this investigation.anuscript received May 12, 2008; revised manuscript received July 16, 2008, accepted July 27, 2008.
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664itral regurgitation (MR) following myocardial infarction
s a complex phenomenon, which arises from an interplay of
nnular dilation, ventricular remodeling, and geometric
lterations of the mitral valve apparatus (1–5). Its occurrence
arries significant morbidity due to progressive heart failure
nd a worse prognosis even when the regurgitation is mild
r without symptoms (6–8). In an attempt to impact the
linical consequences of ischemic MR, conventional treat-
ents have included surgical annuloplasty or, for those with
evere distortion of the mitral valve apparatus, mitral valve
eplacement (9–15). These treatments have been largely
ndertaken in the context of need for open surgical revas-
ularization, but also have been performed independently in
elected patients (16–19). In these instances, early repair is
avored with the goal of interrupting the cycle of heart
ailure due to progressive MR (20–23).
Over the past several years, percutaneous mitral annulo-
lasty for the treatment of functional MR has emerged
24–29). In comparison with open surgery, percutaneous
nnuloplasty has enormous appeal because of the potential
to relieve MR and heart failure
with relatively less invasive
means. Amelioration of the risk
of open heart surgery is particu-
larly important for patients with
functional MR, as these patients
frequently have severe comor-
bidities that increase the risk of
open surgical repair.
The present methods of per-
cutaneous mitral annuloplasty
have centered on reduction of
the valve orifice via the coronary
sinus. Nevertheless, there are
imitations with the current techniques of percutaneous
itral annuloplasty. In many patients, the coronary sinus
ies significantly superior to the plane of the mitral annulus,
articularly near the medial aspects of the mitral annulus
30–32). In these instances, percutaneous coronary sinus
eduction may result in traction on the left atrial wall with
elatively less impact on true mitral annular reduction. This
oss of efficacy may be particularly relevant for treatment of
schemic MR, where regurgitation more frequently affects
he posteromedial portion of the mitral annulus (i.e., P2 and
3 leaflet segments) (3,33,34). In addition, in the lateral
spects of the mitral annulus, the anatomic course of the
oronary sinus becomes more closely apposed to the left
ircumflex coronary artery (30,31). Because of this anatomic
elationship, positioning of percutaneous devices deep (i.e.,
ateral) within the coronary sinus carries the potential for
oronary artery impingement with device deployment (25).
Accordingly, this investigation was undertaken to evalu-
te the feasibility of a different percutaneous approach for
bbreviations
nd Acronyms
-P  anterior-posterior
imension
-C  commissure to
ommissure dimension
CE  intracardiac
chocardiography
R  mitral regurgitation
MVR  percutaneous
itral valve repairitral valve repair. In the present study, we describe a novel nercutaneous method in which an annulus reduction device
s implanted into the myocardium at the posteromedial
itral annulus. This method thereby specifically targets
reatment of the mitral annulus affected by ischemic MR
hile lessening the risk of lateral coronary occlusion.
ethods
ercutaneous mitral annuloplasty device. The percutaneous
itral valve repair (PMVR) device is designed to reduce the
rea of the valve annulus in a manner analogous to open
urgical ring annuloplasty. The PMVR device consists of 4
elical anchors (diameter  length, 2.5 mm  10 mm), 2
oading spacers, a tether rope, and a locking mechanism
Fig. 1). Using endovascular techniques, the implant system
s delivered to the mitral annulus via the coronary sinus and
ight atrium through the use of multiple dedicated 10- to
2-F delivery catheters (Figs. 2 and 3). The distal pair of
nchors is first implanted into the ventricular myocardium
ear the P2 segment of the mitral leaflet from the coronary
inus (Fig. 3). The proximal pair of anchors subsequently is
mplanted near the posteromedial trigone at the coronary
inus from the right atrium. Between these 2 pairs of
nchors, a connecting polyester tether is used to shorten the
nnular distance, thereby effecting favorable change in
itral annular geometry (Fig. 4). Dynamic shortening of
itral annular distance can be performed manually and
eversibly to ascertain the degree of reduction in regurgita-
ion and untoward effects on the coronary sinus or adjacent
oronary arteries (e.g., acute occlusion). The final locking
echanism of the PMVR device is a self-retracting, nitinol
tructure that maintains the cinched load.
nimals. This study was approved by the Local Animal
are and Use Committee. All device implantations were
erformed at Advanced Preclinical Services (Coon Rapids,
innesota) by the study authors. Eleven Yucatan pigs
weight 80.2 to 90.4 kg) were chosen for use in the present
tudy to help approximate human size and minimize the
mpact of animal growth during follow-up. This animal
odel also was chosen for its characteristic proximal coro-
ary sinus anatomy, in which the sinus typically lies superior
o the mitral valve annulus and therefore represents a
orst-case challenge for the translation of the technology to
uman application. Nevertheless, 2 anatomical features of
his model presented significant challenges to proper
MVR device implantation: 1) drainage of a large persistent
ena cava directly into the coronary sinus; and 2) small
iameter of the coronary sinus distal to this vena cava (Fig.
). Because of the large size and location of the persistent
ena cava, implantation of the first set of anchors (distal
air) could only be performed in the coronary sinus in
ositions lateral to the vena cava. In this device location, the
iameter of the coronary sinus is relatively small and would
ot accommodate the size of the delivery catheters in some
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665nstances. The distal end of the delivery catheter when it is
ully articulated is appropriate for the size of the lateral
oronary sinus in humans (8 to 12 mm) (31–35).
rocedures. All studies were performed with animals in the
asting state. Each animal received prophylactic aspirin (325
g daily) beginning 3 days before implantation that was
ontinued throughout the study. All animals also received
ntravenous lidocaine (1 mg/kg bolus and 1 mg/kg/h drip) at
rocedure initiation. Following general anesthesia, mechan-
cal ventilation was maintained on a fraction of inspired
xygen of 40%. Venous access for PMVR device implanta-
ion and for intracardiac echocardiography (ICE) was ob-
ained through sterile surgical cutdown of both the left and
ight internal jugular veins and placement of a 14-F vascular
heath. Arterial access for coronary angiography and pres-
ure monitoring was obtained by similar sterile surgical
utdown of either the carotid or femoral artery and place-
ent of an 8-F vascular sheath. Unfractionated heparin was
dministered to maintain an activated clotting time 200 s
uring the procedure.
Before PMVR implantation, angiography of the coronary
inus and adjacent venous structures was performed to
ted by a biocompatible tether. (B) Top view of PMVR device. (C,D) Guide
uide catheter can be articulated up to 90° to enable back wall support from the
raphy; LV  left ventricle; PMVR  percutaneous mitral valve repair.Figure 1. PMVR Device
(A) Side view of PMVR device showing 4 helical stainless steel screw anchors connec
catheter for implantation of the anchors into the mitral annulus. The distal end of the gFigure 2. Cross-Sectional View of the Implanted PMVR Anchor
Each anchor is implanted from the coronary sinus or right atrium into the
ventricular myocardium at the level of the mitral annulus. Abbreviation asefine the venous anatomy and proximity of the major
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666picardial coronary arteries (Fig. 5). Following anatomical
apping, a 0.035-inch J-tipped guidewire is advanced into
he distal (i.e., lateral) coronary sinus or 1 of its major
ranches. The delivery catheter is advanced into the distal
oronary sinus over this wire, followed by removal of the
uidewire. The delivery catheter contains a flexible, steer-
ble distal segment that can be articulated to 90° (Fig. 1).
his articulation enables back wall support from the coro-
ary sinus during anchor implantation and accurate posi-
ioning of the anchors directly toward the mitral annulus.
ollowing articulation and positioning of the delivery cath-
ter near the P2 segment of the mitral valve, the anchors are
riven into the ventricular myocardium by counterclockwise
otation of a separate deployment tool within the delivery
Figure 3. Schematic of PMVR Implantation
(A) The articulating guide catheter is used to implant 2 anchors near the P2 se
medial trigone. (C) The device is then cinched and released by a set of cutters
Figure 4. Reduction in the Anterior-Posterior (or Septal-Lateral) Diameter o
(A) PMVR anchors are implanted near the P2 segment of the mitral valve and
anterior-posterior (A-P) diameter, posterior-medial shortening (arrowheads), and a ratheter that is coupled to the anchors. This deployment is
eversible for the first 2 turns until barbs protrude, after
hich the anchoring becomes permanent. Before placement
f the proximal set of anchors, a polyester strain-relief
overing is advanced over the tether to distribute the force
rom anchors like a pledget in the coronary sinus. Subse-
uently, in methods analogous to placement of the distal
nchor pair, separate delivery catheters with articulating
eads are used to place the third and fourth anchors
mmediately near the coronary sinus into the posteromedial
rigone from the right atrium. Following deployment of
oth anchor pairs, a cincher catheter is advanced over the
ether to enable dynamic manual cinching. This reversible
aneuver allows evaluation of both the degree of cinching
t of the mitral valve. (B) Two anchors are then implanted into the postero-
eviations as Figure 1.
Mitral Valve Annulus
steromedial trigone. (B) Cinching of the device leads to reduction in thegmenf the
the po
eduction in overall mitral valve area. Abbreviation as in Figure 1.
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667eeded to result in effective mitral annular reduction and to
etect impingement of epicardial coronary arteries before
ermanent anchor cinching. Once a safe and satisfactory
evel of annular reduction is achieved, the cincher catheter is
ightened in the shortened configuration, followed by cut-
ing of the tether by a dedicated cutter catheter, resulting in
ecoupling of the anchor set from the delivery system.
epeat angiography of the coronary venous system and both
rteries was performed for assessment of vascular patency.
valuation of mitral annular reduction. Measurements of
itral valve annular area, mitral annular anterior-posterior
A-P) dimension (also known as the septal-lateral diame-
er), mitral valve commissure to commissure (C-C) dimen-
ion, left ventricular outflow tract diameter, and left ven-
ricular end-diastolic diameter were performed with ICE
mmediately prior to and following PMVR implantation
Fig. 6). Intracardiac echocardiography was used because of
oor echocardiographic windows from both transthoracic
nd transesophageal imaging in these animals. Imaging of
he mitral valve with ICE was obtained with both long- and
hort-axis views similar to the standard acquisition planes
sed in conventional transthoracic echocardiography. End-
xpiratory digital records (average of 3 to 5 samples) of left
entricular end-diastolic pressure and pulmonary capillary
edge pressure were obtained with standard, calibrated
Figure 5. Coronary Sinus Anatomy in the Animal Model
This venogram of the coronary sinus shows the persistent vena cava
(arrowheads), which drains into the coronary sinus. The distal PMVR
anchors needed to be placed lateral to the vena cava because of its large
size. In 2 animals, this portion of the coronary sinus was too small (5-mm
diameter) to accommodate the delivery catheter. L  left; os  occipital
sinus; R  right; other abbreviation as in Figure 1.uid-filled catheters. Assessment of the same parameters ofitral valve geometry with ICE, hemodynamic evaluations,
nd angiography were repeated at 30 and 90 days following
MVR device implantation, followed by animal sacrifice.
dverse events in the periprocedural and follow-up were
ecorded, including occurrence of pericardial effusion or
amponade, atrial or ventricular arrhythmias (tachycardia or
brillation), and development of atrioventricular block.
ross pathology and histology. Following animal sacrifice,
ll hearts were explanted and grossly evaluated for adverse
vents, including device erosion, infection, bleeding, tricus-
id leaflet impingement, arterial occlusion, and thrombosis.
ollowing gross examination, the hearts were pressure-
erfused with 200 ml of lactated ringers’ solution at 80 to
Figure 6. In Vivo PMVR Device Implantation
(A) Caudal ﬂuoroscopy showing the proximal and distal anchors following
implantation. (B) Caudal ﬂuoroscopy showing these anchors following
manual cinching of the PMVR device. (C) Long-axis intracardiac echocardi-
ography showing the LV, left atrium (LA), and the mitral valve at baseline.
(D) Device cinching results in posterior reduction of the mitral annulus
(arrow) seen on intracardiac echocardiography. (E) Short-axis image of the
mitral annulus from intracardiac echocardiography at baseline. (F) Short-
axis image of the mitral annulus from intracardiac echocardiography after
device cinching. There is reduction in the anterior-posterior dimension and
a reduction in the mitral annular area. A  anterior; L  lateral; M 
medial; P  posterior; S  septal; other abbreviations as in Figure 1.
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66820 mm Hg. Pressure fixation of the heart was performed
vernight using 10% neutral buffered formalin at 80 to 120
m Hg. Radiographs of fixed, intact hearts in 2 orthogonal
iews were obtained. The right atrium and coronary sinus
ere incised to enable direct inspection of the PMVR
evice. Tissue surrounding the PMVR device was trimmed,
nd the section was grossly examined, photographed, radio-
raphed, and then processed and embedded in methyl-
ethacrylate. Sections were prepared using EXAKT Sys-
em (EXAKT Technologies, Oklahoma City, Oklahoma)
nd slides were stained with hematoxylin and eosin. Histo-
ogical assessment of the device was performed to evaluate
he implant site to assess implant integrity, inflammation,
nd appearance of fibrous tissue.
ata analysis. Comparisons of continuous variables were
ade with the appropriate 2-sample test: a 2-sample t test
n cases where the variable distributions were symmetric and
Wilcoxon rank sum test otherwise. To adjust for animal
rowth during follow-up evaluations, indexing was per-
ormed by dividing echocardiographic parameters by body
eight. Unless otherwise noted, continuous variables are
eported as mean  SD. Statistical significance was set a
riori at p  0.05.
esults
rocedures. Eleven Yucatan pigs were anesthetized for
mplantation of the PMVR device. In 2 animals, the distal
oronary sinus was too small to accommodate the articulat-
ng sheath of the PMVR device. In a third animal, the
anding zone between the persistent vena cava and circum-
ex artery was too short, prohibiting device implantation in
he sinus without circumflex impingement. Among the 8
nimals that underwent PMVR device implantation, each
mplant was performed successfully without mechanical
omplications, conduction abnormalities, cardiac arrest, loss
f coronary sinus patency, or coronary artery impingement.
here also were no significant changes in left ventricular
nd-diastolic pressure during follow-up (16.6 5.3 mm Hg
s. 18.3  5.1 mm Hg; 90 day vs. baseline; p  0.5).
itral annular area reduction. In each animal, acute implan-
ation of the PMVR device led to an immediate reduction in
he mitral annular area and A-P dimension (p 0.05 for all
aired comparisons) (Fig. 7). Overall, PMVR implantation
cutely resulted in a 19.7  0.1% reduction in mitral valve
nnular area (p  0.0003 vs. baseline) and an 18.8  0.1%
ecrease in the A-P dimension (p  0.0001 vs. baseline),
lthough the C-C dimension remained unchanged (p 
.19 vs. baseline).
During follow-up, there was a significant increase in
ean animal weight (90-day weight vs. baseline; 95.7 5.8
s. 84.1  5.1 kg; p  0.0001). The immediate reductions
n mitral valve annular area and A-P dimension wereaintained at 30 and 90 days (Fig. 7). The C-C dimension vlso was lower at both 30 days and at 90 days in comparison
ith baseline.
ross pathology and histology. In all animals, angiography
emonstrated the coronary sinus and left circumflex artery
o be patent at 30 and 90 days. In all instances, the PMVR
nchors had traversed the coronary sinus wall into the
Figure 7. Parameters of Mitral Annular Reduction
Changes in anterior-posterior dimension (top), commissure-commissure
(middle), and mitral valve area (bottom) immediately after the procedure,
at 30-day follow-up, and at 90-day follow-up. There were signiﬁcant reduc-
tions in the anterior-posterior dimension immediately at the time of the
procedure that persisted in follow-up to 90 days. The decreases in commis-
sure-commissure dimension were not signiﬁcant immediately after the pro-
cedure, but were lower than baseline in follow-up.entricular myocardium at the level of the mitral annulus
(
h
n
m
o
c
a
m
h
D
P
t
T
p
(
m
p
(
b
p
t
t
m
a
a
t
t
s
a
m
a
t
t
w
t
c
c
m
t
p
c
t
t
f
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 1 , N O . 6 , 2 0 0 8
D E C E M B E R 2 0 0 8 : 6 6 3 – 7 2
Sorajja et al.
Novel PMVR
669Figs. 2 and 4). Gross examination at 90 days demonstrated
ealed tissue surrounding the implanted anchors and con-
ecting tether (Fig. 8). There was no evidence of device
igration, tissue erosion, or thrombosis either localized to
r remote from the device implantation (Fig. 8). Histology
onfirmed no migration of the implanted anchors. Small
reas of dense infiltrations of macrophages surrounded by
ature, fibrous connective tissue coverage were present on
istology of the individual components (Fig. 8).
iscussion
ercutaneous mitral annuloplasty has emerged as a poten-
ially less invasive therapy for relief of MR and heart failure.
his innovative technology carries enormous therapeutic
otential given the incidence of myocardial infarction
900,000 hospitalizations per year), the high prevalence of
oderate or severe MR in these patients (12%), and the
oorer prognosis of these patients following onset of MR
36–38). The successful development of an effective, dura-
le percutaneous method of mitral annular reduction would
rovide symptom relief and potentially interrupt the dele-
erious cycle of ventricular remodeling that can occur in
hese patients (23).
Figure 8. Gross and Microscopic Pathology After Device Implantation
(A) Gross view of the coronary sinus 3 months after PMVR device implantation
embedded within the heart or covered by ﬁbrous neointima. Arrow indicates
clip shows the implant surrounded by a ﬁbrous capsule. (C) Cross section of th
surrounded by a compressible outer layer (arrowhead). After 3 months, there
tether. (D) Cross section of the anchor embedded into the myocardium shows good heThe present study demonstrates the feasibility of a novel
ethod for percutaneous mitral annuloplasty. The principal
dvantage of this technology is the direct implantation of an
nnulus reduction device into the myocardium at the pos-
eromedial mitral annulus. The present methodology helps
o overcome circumstances in which the coronary sinus lies
ignificantly superior to the plane of the mitral annulus. In
recent study of patients with significant MR (32), the
inimum distance from the coronary sinus to the mitral
nnulus averaged 7.3  3.9 mm along the entire length of
he coronary sinus and was even greater (9.3  1.0 mm) at
he proximal sinus. These distances may be larger in patients
ith severe MR (32). Because of this superior position of
he sinus relative to the mitral annulus, cinching of the
oronary sinus using some current devices may lead to
inching of the left atrial wall without true reduction in the
itral annular area (i.e., supravalvular stenosis). Variation of
he distance from the coronary sinus to the mitral annulus
oses a challenge to percutaneous approaches from the
oronary sinus (32). The length (10 mm) of the anchors in
he present methodology facilitated their implantation into
he myocardium from the sinus, but can be elongated in
uture applications. Furthermore, the proximal anchor set is
onstrating full patency of the coronary sinus. The device was completely
al tether cut to release PMVR device. (B) Cross-sectional view of the cinch
compatible tether. This tether consists of a tension cord (asterisks) that is
ling with development of a ﬁbrous capsule over the outer layer of thedem
proxim
e bio
is heaaling with no signiﬁcant inﬂammation. Abbreviations as in Figures 1 and 5.
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670mplanted directly into the posteromedial trigone. In the
nimal model of the present investigation, the anatomic
elation of the coronary sinus is similar to that found in
umans, and reduction of the valve orifice area was achieved
y direct device implantation from the coronary sinus into
he mitral annulus.
The present methodology was designed to solely target
he posteromedial aspect of the mitral annulus for several
easons. First, the posteromedial aspect is the most fre-
uently distorted portion of the annulus in patients with
unctional ischemic MR (3,33,34). Surgical treatment with
he aim of correcting this asymmetry has been successful in
hese patients (e.g., Kaye annuloplasty). Second, targeting
f the posteromedial aspect helps to avoid impingement of
he left circumflex coronary artery following device deploy-
ent. In the lateral aspects of the mitral annulus (i.e., near
1 segment of the mitral valve), the course of the circumflex
rtery becomes more intimately related to the coronary
inus. This anatomic relation can be problematic for devices
hat implant in the lateral mitral annulus because the
ircumflex artery lies inferior or between the sinus and
itral annulus in the majority (64%) of patients (30–32).
mportantly, although the present methodology acts region-
lly, there was a significant, 20% reduction in both the
-P (or septal-lateral) mitral annular diameter and in the
verall mitral annular area. In the present study, the reduc-
ions in the A-P annular diameter and the overall mitral
nnular area by percutaneous annuloplasty are comparable
o the results achieved with open surgical repair (39–41).
A major technical challenge to the present methodology
s accurate positioning of each of the 4 helical anchors. The
ong axis of these anchors needs to be directed apically with
inimization of their exposure to the pericardial space.
orrect placement of the device will be challenging in
atients with a coronary sinus that is either very large or too
mall, leading to ineffective back wall support of the artic-
lated delivery catheter. Incorrect placement will result in
ardiac perforation and potentially tamponade, which may
lso occur in patients with a very large distance of the
oronary sinus to the mitral annulus. Of further note,
mplantation of the proximal anchor set also occurs near the
trioventricular node, which could result in complete heart
lock. Each step during percutaneous device insertion,
ncluding manual reduction of the mitral annulus, is com-
letely reversible until the manual reduction is locked. This
llows ongoing assessment of coronary artery patency and
he effect on mitral regurgitation before final deployment.
owever, injury to surrounding structures during initial
evice deployment may still occur. Gross examination and
istology demonstrated the implantation sites to be well
ealed 3 months after device deployment. Preservation of
oronary sinus patency and the low profile of the device also
llow future use of the sinus as may be needed in the
anagement of these patients (e.g., biventricular pacing).The absence of a reproducible animal model of ischemic
itral regurgitation has been a challenge in animal studies
f percutaneous mitral annuloplasty. In some studies, in-
uction of myocardial infarction using both percutaneous
i.e., coronary artery balloon occlusion) and surgical (i.e.,
oronary artery ligation) methods has been used (24,28). In
ur attempts, we were able to create and successfully
liminate ischemic MR with device implantation in 1
nimal (Fig. 9). However, in our own experience and that of
ther investigators, few animals (25% to 40%) survive
hese procedures and develop significant ischemic MR
28,42). Continuous rapid ventricular pacing, which has
Figure 9. Reduction of Ischemic Mitral Regurgitation With Percutaneous
Device Implantation
(Top) Parasternal long-axis view with color-ﬂow echocardiography showing
moderately severe mitral regurgitation (grade 3) present 4 months after
surgical ligation of obtuse marginal arteries. (Bottom) Parasternal long-axis
view with color-ﬂow echocardiography showing elimination of mitral regur-
gitation following device implantation. With device implantation, there is
reduction in the anterior-posterior dimension of the mitral annulus (arrow)
and increased leaﬂet coaptation (arrowhead). Abbreviations as in Figures 1
and 6.
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Novel PMVR
671een used by other investigators, has been shown to cause
entricular dilation and MR (24,25). Its major limitation is
he reliance on global myocardial stunning without regional
nfarction and may not mimic the hemodynamic or mor-
hologic milieu of patients with ischemic MR. In the
resent study, Yucatan pigs were selected for similarities to
uman heart size, the large diameter of the coronary sinus
also similar to humans), and the significant distance be-
ween the sinus and the mitral annulus. Although the effect
n MR was not specifically evaluated, the similarities in size
o human hearts and the significant distance between the
inus and mitral annulus allowed vigorous testing of the
bility to implant into the mitral annulus from the coronary
inus and right atrium.
Functional ischemic MR occurs in 10% to 50% of
atients with myocardial infarction and is associated with a
oorer prognosis even when the degree of regurgitation is
ild (6,42). Despite aggressive medical therapy, advanced
eart failure frequently ensues in these patients. It is
mportant to note that the present methodology does not
irectly address impaired ventricular function and dilation
hat are fundamental to the development of functional MR.
urther ventricular remodeling may result in persistent or
ecurrent MR. Failure to address such remodeling has been
criticism of sinus-based percutaneous approaches (43).
onetheless, we demonstrate reduction of the A-P (or
eptal-lateral) dimension of the mitral annulus with the
resent methodology, and such reduction alone has been
ound to be effective in abolishing chronic ischemic MR
42). Given the heightened mortality of current surgical
perations for ischemic MR, the ability to repair MR
ercutaneously has inherent appeal. Should durable clinical
fficacy of the present approach be demonstrated with
urther investigation, we believe this methodology will have
significant role in the armamentarium of therapies for
atients with symptomatic functional ischemic MR.
onclusions
ercutaneous mitral valve repair with device implantation
nto the ventricular myocardium at the mitral annulus is
easible. With this novel percutaneous method, reduction in
itral annular diameter may be accomplished with a less-
ned risk of circumflex artery impingement, preservation of
oronary sinus patency, and overcoming the technical lim-
tations posed when the coronary sinus lies significantly
uperior to the plane of the mitral annulus.
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